C18orf32 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of the uncharacterised gene C18orf32 in the A-549 lung adenocarcinoma cell background. This knockout model is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited alleles that collectively ablate target gene expression. The polyclonal format provides a rapid and cost-effective means to assess phenotypic consequences of C18orf32 loss without the need for single-cell cloning, making it suitable for initial functional screens and pathway interrogation.
The A-549 cell line, isolated from a 58-year-old Caucasian male with lung adenocarcinoma, displays adherent epithelial morphology and is widely employed as a model of alveolar type II pneumocytes. These cells retain key features of lung adenocarcinoma biology, including oncogenic drivers and signaling aberrations, and are extensively used in cancer biology, drug discovery, and respiratory disease research. The A-549 background thus offers a clinically relevant context for studying genes that may influence lung tumour initiation, progression, or therapeutic response.
C18orf32 is a poorly characterised open reading frame predicted to encode a protein of unknown function. Its molecular interactions, upstream regulators, downstream effectors, and pathway involvement remain undefined. No validated protein partners, post-translational modifications, or transcriptional targets have been reported. Consequently, this knockout model serves as a foundational tool for de novo functional annotation, enabling unbiased approaches such as transcriptomics, proteomics, and phenotypic profiling to uncover its biological role.
In the A-549 lung adenocarcinoma context, disrupting C18orf32 allows researchers to investigate potential contributions to tumour hallmarks, including uncontrolled proliferation, evasion of apoptosis, and metastatic capacity. Comparative analysis of knockout versus wild-type cells can reveal whether C18orf32 acts in a tumour-suppressive or oncogenic manner, and may highlight vulnerabilities that could be exploited therapeutically. The polyclonal nature reduces clonal artifacts and averages out CRISPR off-target effects, strengthening the reliability of observed phenotypes.
Typical downstream evaluations include cell proliferation assays (e.g., MTT), apoptosis detection by Annexin V staining, and wound healing migration assays to gauge metastatic potential. Molecular analyses via western blotting and RT-qPCR enable verification of knockout efficiency and assessment of downstream expression changes. These cells are suitable for functional validation experiments, drug sensitivity profiling, and genetic interaction studies. For additional information or to discuss tailored research solutions, please contact Ascent Research.
